Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 461 to 470 of 797

TitleReference numberPublishedLast updated
Cabozantinib for untreated advanced renal cell carcinomaTA542
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Dinutuximab beta for treating neuroblastomaTA538
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Dupilumab for treating moderate to severe atopic dermatitisTA534
Ocrelizumab for treating relapsing–remitting multiple sclerosisTA533
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531

Results per page

  1. 10
  2. 25
  3. 50
  4. All